Related Experiment Videos
Bone mineral density in steroid-dependent asthma assessed by peripheral quantitative computed tomography
H Tsugeno1, M Nakai, M Okamoto
1Division of Medicine, Okayama University Medical School, Tottori, Japan.
The European Respiratory Journal
|November 26, 1999
Summary
Systemic glucocorticoid therapy causes bone loss, affecting both trabecular and cortical bone density. This loss, particularly in older patients, increases fracture risk, highlighting the need for monitoring bone health during long-term steroid use.
Area of Science:
- Endocrinology
- Bone Metabolism
- Pharmacology
Background:
- Chronic systemic glucocorticoid use is a significant cause of bone loss and fractures.
- Understanding the predictive factors for glucocorticoid-induced bone loss is crucial for patient management.
Purpose of the Study:
- To identify variables predicting bone loss in patients on systemic glucocorticoid therapy.
- To quantify changes in cortical and trabecular bone using peripheral quantitative computed tomography (pQCT).
Main Methods:
- Eighty-four asthmatic patients receiving systemic glucocorticoid therapy were studied.
- Peripheral quantitative computed tomography (pQCT) measured bone mineral density (BMD) in cortical and trabecular bone.
- Multiple regression analysis identified predictive variables for bone loss.
Main Results:
- Cumulative glucocorticoid dose correlated with decreased bone mineral density (p<0.05) and trabecular bone density (p<0.01).
- In patients aged 65 and older, cumulative dose correlated with vertebral fractures, total BMD, and cortical BMD (p<0.05, p<0.01).
- Glucocorticoid therapy reduced both trabecular and cortical bone mineral density, with cortical bone loss potentially explaining increased fracture incidence.
Conclusions:
- Systemic glucocorticoids negatively impact both trabecular and cortical bone density.
- Loss of cortical bone, essential for skeletal strength, is implicated in the elevated fracture risk associated with long-term glucocorticoid treatment.
- Monitoring bone density, especially cortical bone, is vital in patients undergoing chronic glucocorticoid therapy.